Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "Mpower"

539 News Found

Thermo Fisher and NVIDIA team up to supercharge labs with AI
Digitisation | January 14, 2026

Thermo Fisher and NVIDIA team up to supercharge labs with AI

Artificial intelligence coupled with laboratory automation will transform how scientific work is performed


Leeford Healthcare bets Rs. 200 crore on orthopedic & mobility aids
Healthcare | January 09, 2026

Leeford Healthcare bets Rs. 200 crore on orthopedic & mobility aids

Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign


Dr. Lal PathLabs launches tech-driven personalized wellness center 'Sovaaka'
News | January 07, 2026

Dr. Lal PathLabs launches tech-driven personalized wellness center 'Sovaaka'

Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks


WuXi Biologics secures ISO 20400 certification
Sustainability | January 07, 2026

WuXi Biologics secures ISO 20400 certification

WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management


StimLabs secures FDA nod for groundbreaking human umbilical cord-derived device
Medical Device | January 01, 2026

StimLabs secures FDA nod for groundbreaking human umbilical cord-derived device

Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment


Ginkgo Bioworks teams with Carnegie Mellon on cancer detection program
R&D | December 27, 2025

Ginkgo Bioworks teams with Carnegie Mellon on cancer detection program

The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors


GSK’s Exdensur gains FDA nod for severe asthma with just two doses a year
Drug Approval | December 20, 2025

GSK’s Exdensur gains FDA nod for severe asthma with just two doses a year

The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials